Albiglutide: a unique GLP-1 receptor agonist

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

(2015) Rhonda Bentley-Lewis et al.   AMERICAN HEART JOURNAL

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2015) Michael A. Nauck et al.   DIABETOLOGIA

Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

(2015) Yahiya Y. Syed et al.   DRUGS

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis

(2015) Miles Fisher et al.   Lancet Diabetes & Endocrinology

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

(2015) Sri Harsha Tella et al.   Therapeutic Advances in Endocrinology and Metabolism

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

(2015) Kate Gurney et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

(2015) Tara Gurung et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men

(2014) Robert E Steinert et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Albiglutide

(2014) Jennifer M. Trujillo et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

(2014) Lawrence A. Leiter et al.   DIABETES CARE

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

(2014) P. D. Home et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

(2014) J. Reusch et al.   DIABETES OBESITY & METABOLISM

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

(2014) M. Hompesch et al.   DIABETES OBESITY & METABOLISM

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

(2014) Peter N. Weissman et al.   DIABETOLOGIA

Albumin and its application in drug delivery

(2014) Darrell Sleep   Expert Opinion on Drug Delivery

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

(2014) Laurie L. Baggio et al.   JOURNAL OF CLINICAL INVESTIGATION

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

(2014) Malcolm A. Young et al.   POSTGRADUATE MEDICINE

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

(2013) M. M. Umapathysivam et al.   DIABETES

Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones

(2013) C. S. Marathe et al.   DIABETES CARE

The path to approval of new drugs for diabetes

(2013) Marc Rendell   Expert Opinion On Drug Safety

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

(2013) M E J Lean et al.   INTERNATIONAL JOURNAL OF OBESITY

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

(2013) Michael Grimm et al.   POSTGRADUATE MEDICINE

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

(2013) Martin Lorenz et al.   REGULATORY PEPTIDES

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

(2013) Brønden Petersen et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Absorption, Distribution, Metabolism, and Excretion (ADME) Studies of Biotherapeutics for Autoimmune and Inflammatory Conditions

(2012) Yulia Vugmeyster et al.   AAPS Journal

Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics

(2012) Xin Xu et al.   AAPS Journal

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

(2012) J. Rosenstock et al.   DIABETES CARE

Regulation of glucagon secretion by incretins

(2011) J. J. Holst et al.   DIABETES OBESITY & METABOLISM

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

(2011) Hirenkumar K. Makadia et al.   Polymers

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Assessment of Older Adults' Knowledge of and Preferences for Medication Management Tools and Support Systems

(2009) Susan L Lakey et al.   ANNALS OF PHARMACOTHERAPY

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Exenatide efficacy and safety: a systematic review

(2009) S. L. Norris et al.   DIABETIC MEDICINE

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET